AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease pipelines, the company said, with oncology seeing 22% growth. Cardiovascular, renal and metabolism (CVRM) experienced 21% growth, R&I 24% and rare disease 14%.

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

AstraZeneca (NASDAQ:AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States by the end of 2026. The U.K. drugmaker said the investment was part of its initiative to achieve $80B in total revenue by 2030.